Canna~Fangled Abstracts

Peripheral versus central mechanisms of the cannabinoid type 2 receptor agonist AM1710 in a mouse model of neuropathic pain

By September 25, 2020 September 27th, 2020 No Comments

doi: 10.1002/brb3.1850.

Online ahead of print.
Affiliations

Free article

Abstract

The CB2 R agonist AM1710, examined in animal models of peripheral neuropathy, is effective in controlling aberrant light touch sensitivity, referred to as mechanical allodynia. However, nonspecific binding of AM1710 to CB1 R, either peripherally or centrally, could be partially responsible for the analgesic effects of AM1710. Thus, we sought to determine in mice whether spinal (intrathecal; i.t.) or peripheral AM1710 administration could lead to anti-allodynia by reducing the protein expression of spinal and dorsal root ganglia (DRG) proinflammatory cytokines and elevating the anti-inflammatory cytokine interleukin-10 (IL-10) in the absence of CB1 R. Macrophage cell cultures were examined to characterize AM1710-mediated suppression of the proinflammatory cytokine tumor necrosis factor-alpha (TNF-α). Either i.p. or i.t. AM1710 reversed CCI-induced mechanical allodynia to sham levels in CB1 R (-/-), (+/-), (+/+) mice. CCI-induced neuropathy decreased IL-10 immunoreactivity (IR) in the dorsal root ganglia (DRG) and the dorsal horn of the spinal cord, with i.t. AM1710 restoring basal IL-10 IR. CCI-induced elevations in proinflammatory cytokine IR were decreased within the spinal cord only after i.t. AM1710 in all mouse genotypes. Meanwhile, within DRG tissue from neuropathic mice, proinflammatory cytokines were decreased following either i.p. or i.t. AM1710. Analysis of cultured supernatants revealed AM1710 decreased TNF-alpha protein. We conclude that CB1 R is dispensable for either peripheral or central anti-allodynic actions of AM1710 in neuropathic mice. Cannabinoid CB2 R agonists produce heightened spinal IL-10 which may be clinically relevant to successfully treat neuropathic pain.

 

Keywords: MCP-1/CCL-2, cannabinoid, mouse, paraffin immunohistochemistry, spectral analysis

References

REFERENCES

    1. Abbadie, C., Bhangoo, S., De Koninck, Y., Malcangio, M., Melik-Parsadaniantz, S., & White, F. A. (2009). Chemokines and pain mechanisms. Brain Research Reviews, 60, 125-134. https://doi.org/10.1016/j.brainresrev.2008.12.002
    1. Abdallah, B., Hassan, A., Benoist, C., Goula, D., Behr, J. P., & Demeneix, B. A. (1996). A powerful nonviral vector for In Vivo gene transfer into the adult mammalian brain: Polyethylenimine. Human Gene Therapy, 7, 1947-1954.
    1. Ahmed, M. M., Rajpal, S., Sweeney, C., Gerovac, T. A., Allcock, B., McChesney, S., … Resnick, D. K. (2010). Cannabinoid subtype-2 receptors modulate the antihyperalgesic effect of WIN 55,212-2 in rats with neuropathic spinal cord injury pain. The Spine Journal, 10(12), 1049-1054. https://doi.org/10.1016/j.spinee.2010.08.015
    1. Beltramo, M. (2009). Cannabinoid type 2 receptor as a target for chronic – pain. Mini Reviews in Medicinal Chemistry, 9(1), 11-25.
    1. Beutler, A. S., Banck, M. S., Walsh, C. E., & Milligan, E. D. (2005). Intrathecal gene transfer by adeno-associated virus for pain. Current Opinion in Molecular Therapeutics, 7(5), 431-439.

LinkOut – more resources

Leave a Reply

en English